Reblozyl (luspatercept) — Medical Benefit Coverage Criteria
Defines medical benefit coverage, initial and continuation criteria, quantity limits, authorization periods, and applicable billing codes for Reblozyl (luspatercept) for treating anemia in beta thalassemia and myelodysplastic syndromes (MDS). Applies to providers requesting coverage under this payer policy.
No material clinical or coverage changes in this revision.
Coverage Criteria for Reblozyl (luspatercept)
inv-01: Initial Therapy - Beta Thalassemia
Covered when ALL of the following are met
Initial criteria for beta thalassemia
- Prescriber: Prescribed by, or in consultation with, a hematologist
- Diagnosis of beta thalassemia or hemoglobin E/beta thalassemia
- Transfusion dependence: Documentation of transfusion dependence
- Age ≥ 18 years
inv-02: Initial Therapy - MDS
Covered when ALL of the following are met
Initial criteria for MDS
- Prescriber: Prescribed by, or in consultation with, a hematologist or oncologist
- Diagnosis of myelodysplastic syndrome (MDS)
- Risk: Has very low- to intermediate-risk disease
- Age ≥ 18 years old
- Transfusion requirement: Documentation of symptomatic anemia requiring transfusion of ≥ 2 red blood cell units over an 8-week period≥2 units/8 weeks
- Biomarker/previous therapy: Documentation of one of: (1) ring sideroblasts < 15% (or ring sideroblasts < 5% with SF3B1 mutation) with both: (a) serum erythropoietin ≤ 500 mU/mL and (b) an erythropoiesis-stimulating agent was ineffective, contraindicated, or not tolerated; OR (2) ring sideroblasts ≥ 15% (or ≥ 5% with an SF3B1 mutation)
inv-03: Continuation Therapy - Beta Thalassemia
Covered when ALL of the following are met
Continuation criteria for beta thalassemia
- Diagnosis of beta thalassemia or hemoglobin E/beta thalassemia
- Response: Documentation of a positive clinical response as evidenced by a reduction in red blood cell transfusions from baseline
inv-04: Continuation Therapy - MDS
Covered when ALL of the following are met
Continuation criteria for MDS
- Diagnosis of anemia with very low- to intermediate-risk myelodysplastic syndrome (MDS)
- Response: Documentation of a positive clinical response as evidenced by a reduction in red blood cell transfusions from baseline
The policy includes no explicit exclusions for Reblozyl (luspatercept); the document does not list any conditions, populations, or clinical scenarios that are specifically excluded from coverage beyond the stated eligibility criteria for the covered indications.
Coverage is contingent on meeting the stated criteria for the applicable indication. Therefore, if the required criteria are not met (for example, absence of documented transfusion dependence for beta thalassemia, or failure to meet the MDS transfusion, risk, biomarker, or prior ESA requirements), the therapy is not covered under this policy.
Billing and Coding
| J0896 | Injection, luspatercept-aamt, 0.25 mg |
Prior Authorization, Documentation, and Provider Requirements
Prior authorization and approval periods
Prior authorization is required for luspatercept; submit documentation that meets the policy's initial-approval criteria. A patient weight must be provided with the authorization request. Initial approvals are for six months; continuation approvals (if criteria for response are met) are for one year.
- Provide patient weight with the request.
- Initial authorization period: 6 months.
- Continuation authorization period: 1 year.
Prior ESA requirement/justification for certain MDS patients
For MDS patients with ring sideroblasts <15% (or <5% when an SF3B1 mutation is present), document a serum erythropoietin level ≤500 mU/mL and that an erythropoiesis‑stimulating agent (ESA) was ineffective, contraindicated, or not tolerated before luspatercept will be approved.
- Ring sideroblasts <15% (or <5% with SF3B1 mutation) requires both: serum erythropoietin ≤500 mU/mL and prior ESA ineffective/contraindicated/not tolerated.
Required clinical documentation
Include comprehensive clinical documentation with the authorization request: diagnosis, patient age, and that the drug was prescribed by or in consultation with a hematologist or oncologist. For transfusion-dependent patients, document transfusion dependence (for MDS specify number of RBC units over an 8‑week period); include ring sideroblast percentage and/or SF3B1 mutation status and serum erythropoietin when applicable, plus prior ESA response or contraindication.
- Diagnosis and age (≥18 years).
- Prescriber: hematologist or oncologist (or consult).
- Transfusion dependence — for MDS document ≥2 RBC units over an 8‑week period.
- Ring sideroblast percentage and/or SF3B1 mutation status when applicable.
- Serum erythropoietin level when applicable and documentation of prior ESA response/contraindication/intolerance.
Documentation gaps may trigger denial
Applications lacking documentation that satisfies the initial coverage criteria may be denied. Examples include missing evidence of transfusion dependence for beta thalassemia, absence of the specified ≥2 RBC units/8‑week transfusion record for MDS, or missing ring sideroblast/SF3B1 and EPO/ESA documentation required for the MDS pathways.
- No documentation of transfusion dependence for beta thalassemia.
- For MDS, failure to document symptomatic anemia requiring ≥2 RBC units over 8 weeks.
- Missing ring sideroblast percentage, SF3B1 status, serum erythropoietin, or prior ESA effectiveness/contraindication/intolerance.
Background and Indications
Reblozyl (luspatercept) is described in the policy as indicated for treatment of anemia in two settings: adults (≥18 years) with beta thalassemia or hemoglobin E/beta thalassemia who have documented transfusion dependence; and adults (≥18 years) with very low- to intermediate-risk myelodysplastic syndromes (MDS) with symptomatic anemia requiring transfusion. For MDS, eligibility depends on transfusion burden (≥2 units of red blood cells over an 8‑week period) and either specific bone marrow findings (ring sideroblasts ≥15%, or ≥5% with an SF3B1 mutation) or ring sideroblasts below threshold combined with a serum erythropoietin ≤500 mU/mL and prior erythropoiesis‑stimulating agent (ESA) failure, contraindication, or intolerance.
Definitions and Clinical Terms
Biomarker and Laboratory Requirements
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.